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A team of rivals at the kinetochore
P
rotein phosphatase 
I (PPI) is specifi  -
cally recruited to 
kinetochores to counteract 
the Aurora B kinase, report 
Liu et al. The opposing 
enzymes combine to ensure 
chromosomes segregate correctly in mitosis.
In metaphase, the kinetochores of sister chromatids must con-
nect to microtubules emanating from opposite spindle poles. Incor-
rect attachments are eliminated by Aurora B, which phosphorylates 
kinetochore proteins to reduce their microtubule-binding capacity. 
Correct attachments generate tension and pull the kinetochore pro-
teins out of Aurora B’s reach, but phosphate groups added by the ki-
nase must be removed to stabilize the kinetochore–microtubule inter-
action. PPI is a good candidate for this job, but its role at kinetochores 
has been diffi  cult to study as it has multiple functions in the cell.
Liu et al. found that the kinetochore protein KNL1 binds and 
recruits PPI. Preventing PPI targeting to kinetochores by mutating 
KNL1 resulted in increased phosphorylation of Aurora B substrates 
and unstable microtubule attachments, even at kinetochores aligned 
correctly on the mitotic spindle. PPI is therefore needed to reverse 
Aurora B activity and stabilize microtubules at kinetochores, but 
PPI’s recruitment is itself regulated by Aurora B, the researchers 
found. Phosphorylation of KNL1 blocked its association with PP1, 
indicating that Aurora B excludes PP1 from kinetochores until 
correct attachments and tension pull KNL1 away from the kinase.
Small amounts of PPI could then dephosphorylate KNL1 
and promote the recruitment of further PPI molecules, says author 
Michael Lampson. This might make the transition between 
stable and unstable microtubule binding sharper, a proposition 
Lampson and co-author Iain Cheeseman now want to investigate 
using phospho-site mutants of KNL1.
Liu, D., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201001006.
Disuse TWEAKs muscle loss
M
ittal et al. iden-
tify a cytokine 
signaling path-
way that induces the break-
down of disused skeletal 
muscle. Blocking this path-
way could prevent immo-
bilized patients from losing 
their muscle tissue.
Skeletal muscle wastes away when its activity is reduced 
by—for example—the loss of stimulatory motor neurons. 
Although the mechanism by which muscle fi  bers break down 
is understood fairly well, how the process is triggered remains 
unknown. The TNF-related cytokine TWEAK can induce muscle 
loss, but whether it does so in disused muscle is unclear.
Mittal et al. compared how mice expressing different 
amounts of TWEAK responded when the nerve innervating their 
hind legs was severed. Mice producing excess TWEAK lost their 
muscle more quickly than wild-type animals, whereas mice lack-
ing this cytokine were largely protected from muscle breakdown. 
TWEAK levels also correlated with the amount of fi  brosis, anoth-
er common symptom of muscle disuse. Inhibiting TWEAK with 
a neutralizing antibody was suffi  cient to block muscle loss fol-
lowing denervation, suggesting that the pathway could be a viable 
therapeutic target. TWEAK signaling activated the transcription 
factor NF-    B to up-regulate the ubiquitin ligase MuRF-1, which 
targets components of the muscle thick fi  lament for destruction.
Rather than stimulating TWEAK production, denervation 
increases expression of the cytokine’s receptor, Fn14. The next 
question, says lead author Ashok Kumar, is how this receptor is 
up-regulated when muscle use is curtailed.
Mittal, A., et al. 2010. J. Cell Biol. doi:10.1083/jcb.200909117.
Muscle fibers grow smaller after 
denervation (left), but are protected 
when TWEAK activity is inhibited by a 
neutralizing antibody (right).
Arf and Miz1 cause cells to lose their grip
T
wo proteins that 
act independently 
to arrest the cell 
cycle can combine to in-
hibit cell adhesion and 
drive apoptosis instead, 
say Herkert et al.
The transcription 
factor Miz1 arrests dam-
aged cells by inducing the 
production of cyclin-dependent kinase (Cdk) inhibitors. The 
tumor suppressor Arf, meanwhile, can either arrest cells or kill 
them following oncogenic stress, although what determines each 
of these two outcomes remains unknown. Miz1 and Arf have 
several interacting proteins in common, but Herkert et al. found 
that the two proteins also bind each other directly.
Surprisingly, rather than synergizing to block the cell cycle 
more effi  ciently, Arf prevented Miz1 from activating Cdk inhibitors. 
Instead, when combined, Arf and Miz1 assembled into a DNA-
binding complex that silenced genes by inducing changes in their 
histone methylation states. As well as repressing the Cdk inhibitor 
genes, this complex also switched off many genes associated with 
cell–cell and cell–matrix adhesions, causing cells expressing Arf 
and Miz1 to lose their attachments and undergo apoptosis. This 
pathway could help tissues eliminate cells that have picked up 
potentially oncogenic mutations, the authors suggest.
Assembly of the repressive complex relied on the interaction 
of both Arf and Miz1 with the transcription factor Myc, suggesting 
that Myc levels may be crucial in switching Arf’s function from 
arrest to cell death. In addition, association with Arf and Myc 
triggered Miz1’s modifi   cation by the ubiquitin-like molecule 
SUMO. Lead author Martin Eilers now plans to investigate how 
this modifi  cation helps the complex repress its target genes.
Herkert, B., et al. 2010. J. Cell Biol. doi:10.1083/jcb.200908103.
PPI is lost from kinetochores when its 
binding site on KNL1 is mutated (right).
Myc (red) and Miz1 (green) are recruited 
by Arf (right panel) into heterochromatin 
complexes that repress cell adhesion 
genes and initiate apoptosis.